4/26
09:39 am
tvgn
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments [Yahoo! Finance]
Low
Report
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments [Yahoo! Finance]
4/26
09:23 am
tvgn
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
High
Report
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
4/11
08:14 am
tvgn
Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers [Yahoo! Finance]
Medium
Report
Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers [Yahoo! Finance]
4/11
08:05 am
tvgn
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
Low
Report
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
4/3
08:05 am
tvgn
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
High
Report
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
3/28
08:05 am
tvgn
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
Medium
Report
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
3/27
09:32 am
tvgn
Tevogen Bio Announces Series A-1 Preferred Stock Investment [Yahoo! Finance]
High
Report
Tevogen Bio Announces Series A-1 Preferred Stock Investment [Yahoo! Finance]
3/20
07:00 am
tvgn
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
Low
Report
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
3/5
08:00 am
tvgn
Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
Medium
Report
Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
2/29
08:08 am
tvgn
With a 86% stake, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insiders have a lot riding on the company [Yahoo! Finance]
Low
Report
With a 86% stake, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insiders have a lot riding on the company [Yahoo! Finance]
2/21
07:00 am
tvgn
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
Low
Report
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
2/17
12:17 am
tvgn
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
Medium
Report
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
2/15
09:25 am
tvgn
Tevogen Bio Announces $8 Million Equity Investment
High
Report
Tevogen Bio Announces $8 Million Equity Investment